TREATMENT OF IDIOPATHIC RETINAL VASCULITIS, ANEURYSMS, AND NEURORETINITIS (IRVAN) WITH PHOTOCOAGULATION IN COMBINATION WITH SYSTEMIC IMMUNOSUPPRESSION.


Journal

Retinal cases & brief reports
ISSN: 1937-1578
Titre abrégé: Retin Cases Brief Rep
Pays: United States
ID NLM: 101298744

Informations de publication

Date de publication:
2020
Historique:
pubmed: 21 12 2017
medline: 17 7 2021
entrez: 21 12 2017
Statut: ppublish

Résumé

Idiopathic retinal vasculitis, aneurysms, and neuroretinitis syndrome is a very rare primary retinal vasculitis. It seems to evolve in stages, where there is initially a florid vasculitis associated with aneurysm formation. Neuroretinitis and macula edema are common features. Subsequently, retinal ischemia ensues, leading to neovascularization. If untreated, further sight-threatening complications occur, including traction retinal detachment and secondary glaucoma. Here, we describe a patient with early idiopathic retinal vasculitis, aneurysms, and neuroretinitis syndrome, who was treated with a combination of systemic immunosuppression and localized photocoagulation. There was substantial regression of the aneurysms and improvement of the macular edema. Treatment of the disorder should be based on the clinical stage and complications of the disorder. As shown here, a multidisciplinary approach can be very helpful in managing patients with this severe sight-threatening disorder.

Sections du résumé

BACKGROUND BACKGROUND
Idiopathic retinal vasculitis, aneurysms, and neuroretinitis syndrome is a very rare primary retinal vasculitis. It seems to evolve in stages, where there is initially a florid vasculitis associated with aneurysm formation. Neuroretinitis and macula edema are common features. Subsequently, retinal ischemia ensues, leading to neovascularization. If untreated, further sight-threatening complications occur, including traction retinal detachment and secondary glaucoma.
METHODS AND RESULTS RESULTS
Here, we describe a patient with early idiopathic retinal vasculitis, aneurysms, and neuroretinitis syndrome, who was treated with a combination of systemic immunosuppression and localized photocoagulation. There was substantial regression of the aneurysms and improvement of the macular edema. Treatment of the disorder should be based on the clinical stage and complications of the disorder.
CONCLUSIONS CONCLUSIONS
As shown here, a multidisciplinary approach can be very helpful in managing patients with this severe sight-threatening disorder.

Identifiants

pubmed: 29261555
doi: 10.1097/ICB.0000000000000692
pii: 01271216-202001440-00011
doi:

Substances chimiques

Coloring Agents 0
Immunosuppressive Agents 0
Mycophenolic Acid HU9DX48N0T
Indocyanine Green IX6J1063HV
Methylprednisolone X4W7ZR7023

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

334-338

Références

Samuel MA, et al. Idiopathic retinitis, vasculitis, aneurysms, and neuroretinitis (IRVAN): new observations and a proposed staging system. Ophthalmology 2007;114:1526–1529.e1521.
Kincaid J, Schatz H. Bilateral retinal arteritis with multiple aneurysmal dilatations. Retina 1983;3:171–178.
Nourinia R, et al. Idiopathic retinal vasculitis, aneurysms and neuroretinitis syndrome associated with positive perinuclear antineutrophil cytoplasmic antibody. J Ophthalmic Vis Res 2011;6:330–333.
Soheilian M, et al. Idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome associated with positive perinuclear antineutrophil cytoplasmic antibody (P-ANCA). Retin Cases Brief Rep 2010;4:198–201.
Chang TS, et al. Idiopathic retinal vasculitis, aneurysms, and neuro-retinitis. Retinal Vasculitis Study. Ophthalmology 1995;102:1089–1097.
Sashihara H, Hayashi H, Oshima K. Regression of retinal arterial aneurysms in a case of idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN). Retina 1999;19:250–251.
Tomita M, et al. Long term follow up in a case of successfully treated idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN). Br J Ophthalmol 2004;88:302–303.
Basha M, et al. Management of IRVAN syndrome with observation. Ophthalmic Surg Lasers Imaging Retina 2014;45:e18–e22.
Empeslidis T, et al. Dexamethasone intravitreal implant for idiopathic retinal vasculitis, aneurysms, and neuroretinitis. Eur J Ophthalmol 2013;23:757–760.
Moosavi M, et al. Unilateral idiopathic retinal vasculitis, aneurysms, and neuroretinitis syndrome (IRVAN) in a young female. J Curr Ophthalmol 2015;27:63–66.
Karagiannis D, et al. Ranibizumab for idiopathic retinal vasculitis, aneurysms, and neuroretinitis: favorable results. Eur J Ophthalmol 2010;20:792–794.
Sawhney GK, et al. Combination anti-VEGF and corticosteroid therapy for idiopathic retinal vasculitis, aneurysms, and neuroretinitis syndrome. Ophthalmic Surg Lasers Imaging Retina 2013;44:599–602.
Cheema RA, Al-Askar E, Cheema HR. Infliximab therapy for idiopathic retinal vasculitis, aneurysm, and neuroretinitis syndrome. J Ocul Pharmacol Ther 2011;27:407–410.
Singh R, et al. Vanishing retinal arterial aneurysms with anti-tubercular treatment in a patient presenting with idiopathic retinal vasculitis, aneurysms, and neuroretinitis. J Ophthalmic Inflamm Infect 2016;6:8.
Vichare N, et al. A rare case of idiopathic retinal vasculitis, aneurysms and neuroretinitis (IRVAN) syndrome. Med J Armed Forces India 2015;71:S257–S260.
Saatci AO, et al. Single bilateral dexamethasone implant in addition to panretinal photocoagulation and oral azathioprine treatment in IRVAN syndrome. Case Rep Ophthalmol 2015;6:56–62.
Xia Y, et al. Fluorescein photodiagnosis of idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome: a case report and long-term outcome of photocoagulation therapy. Photodiagnosis Photodyn Ther 2016;16:15–16.
MacIver S, Bass SJ, Sherman J. Visual acuity recovery in a case of idiopathic retinal vasculitis aneurysms and neuroretinitis. Optom Vis Sci 2012;89:E356–E363.

Auteurs

Rohan Ameratunga (R)

Grafton Specialists, Auckland, New Zealand; and.

Mark Donaldson (M)

Eye Doctors, Ascot Hospital, Auckland, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH